10x Genomics, Inc. (NASDAQ:TXG) Given Consensus Recommendation of “Hold” by Brokerages

Shares of 10x Genomics, Inc. (NASDAQ:TXG) have been given an average recommendation of “Hold” by the seventeen brokerages that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and seven have issued a buy rating on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $20.57.

Several equities research analysts have recently issued reports on TXG shares. Leerink Partnrs downgraded shares of 10x Genomics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 13th. The Goldman Sachs Group decreased their target price on shares of 10x Genomics from $16.00 to $14.00 and set a “sell” rating for the company in a research report on Wednesday, October 30th. JPMorgan Chase & Co. decreased their target price on shares of 10x Genomics from $14.00 to $12.00 and set a “neutral” rating for the company in a research report on Thursday, February 13th. UBS Group decreased their target price on shares of 10x Genomics from $20.00 to $14.00 and set a “neutral” rating for the company in a research report on Thursday, February 13th. Finally, Barclays decreased their target price on shares of 10x Genomics from $19.00 to $18.00 and set an “overweight” rating for the company in a research report on Monday, February 10th.

Institutional Trading of 10x Genomics

A number of hedge funds have recently modified their holdings of the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of 10x Genomics by 10.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,116,573 shares of the company’s stock worth $30,394,000 after buying an additional 193,588 shares during the last quarter. Voloridge Investment Management LLC lifted its stake in shares of 10x Genomics by 12.1% during the 4th quarter. Voloridge Investment Management LLC now owns 1,585,965 shares of the company’s stock worth $22,774,000 after buying an additional 171,161 shares during the last quarter. Twinbeech Capital LP acquired a new stake in shares of 10x Genomics during the 4th quarter worth about $180,000. Two Sigma Advisers LP lifted its stake in shares of 10x Genomics by 240.6% during the 4th quarter. Two Sigma Advisers LP now owns 1,236,200 shares of the company’s stock worth $17,752,000 after buying an additional 873,200 shares during the last quarter. Finally, Two Sigma Investments LP increased its position in 10x Genomics by 291.2% during the fourth quarter. Two Sigma Investments LP now owns 1,319,487 shares of the company’s stock worth $18,948,000 after acquiring an additional 982,203 shares during the period. Institutional investors and hedge funds own 84.68% of the company’s stock.

10x Genomics Stock Performance

Shares of NASDAQ:TXG opened at $12.07 on Wednesday. The company has a 50 day moving average price of $14.52 and a two-hundred day moving average price of $17.22. 10x Genomics has a 52 week low of $10.80 and a 52 week high of $48.42. The company has a market capitalization of $1.46 billion, a PE ratio of -7.89 and a beta of 1.85.

10x Genomics (NASDAQ:TXG) last issued its quarterly earnings data on Wednesday, February 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.07% and a negative net margin of 28.93%. On average, sell-side analysts forecast that 10x Genomics will post -1.43 earnings per share for the current year.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.